Deucravacitinib (Sotyktu) for Psoriasis: How This Oral TYK2 Inhibitor Works

Deucravacitinib, sold internationally as Sotyktu, is the first oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis — a once-daily tablet that works through a mechanism distinct from both older oral drugs and the injectable biologics covered elsewhere on this site. For patients who want strong, consistent results without regular injections, or who have not done well on other oral options, deucravacitinib represents a genuinely new category of psoriasis treatment rather than just another drug in an existing class. This guide explains how it works, what the clinical trial evidence actually shows, its safety profile, and what it means for patients in India weighing it alongside Ayurvedic or integrative care.

What Is Deucravacitinib and How Does It Work?

Deucravacitinib is a highly selective inhibitor of tyrosine kinase 2 (TYK2), a signaling enzyme that sits inside the IL-23 and type I interferon pathways that drive much of the inflammation seen in plaque psoriasis. What makes it mechanistically distinct is how it blocks TYK2: instead of binding the enzyme’s active ATP-binding site the way conventional JAK inhibitors such as tofacitinib do, deucravacitinib binds an allosteric regulatory domain on the enzyme. This allosteric approach allows it to shut down TYK2 signaling selectively while largely sparing the related JAK1, JAK2, and JAK3 enzymes that those older oral drugs also block — and which are responsible for much of their broader side-effect profile. Because TYK2 sits specifically in the IL-23 and interferon pathways rather than the wider cytokine signaling network, deucravacitinib’s downstream effect on the immune system is comparable in concept to injectable IL-23 inhibitors, but delivered as a tablet rather than an injection.

Deucravacitinib Dosing for Plaque Psoriasis

The dosing approved in deucravacitinib’s pivotal trials and current label is straightforward compared with the step-up schedules used by many biologics:

• 6 mg taken orally once daily, with or without food
• No injection, no loading dose, and no routine requirement for refrigerated storage
• Response is typically assessed over 16 to 24 weeks before deciding whether to continue

This is general label information, not a personal prescription — your dermatologist will confirm candidacy through baseline screening (including tuberculosis testing) and set the actual treatment plan based on your health history and response.

How Well Does Deucravacitinib Actually Work?

Deucravacitinib’s efficacy was established in two 52-week phase 3 trials, POETYK PSO-1 and POETYK PSO-2, which compared it against both placebo and apremilast — making it one of the few psoriasis drugs with head-to-head data against another oral systemic treatment rather than only placebo. At week 16, 58.7% of patients on deucravacitinib reached PASI 75 (a 75% reduction in psoriasis severity) in PSO-1, and 53.6% did in PSO-2, compared with only 12.7% and 9.4% respectively on placebo. By week 24, after patients on placebo had crossed over to active treatment, deucravacitinib’s PASI 75 response had climbed further and clearly outperformed apremilast in both trials — 69.0% versus 38.1% in PSO-1, and 59.3% versus 37.8% in PSO-2. Longer-term follow-up data presented by Bristol Myers Squibb has shown these response rates holding up through three and four years of continued treatment in patients who remained on the drug, with a safety profile that stayed consistent over that period.

Who Is Deucravacitinib Typically Prescribed For?

Deucravacitinib is approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and the FDA has since expanded its approval to include adults with active psoriatic arthritis as well, giving it relevance for patients managing both skin and joint symptoms, similar to how dermatologists think about other therapies used across psoriatic arthritis. In practice, it tends to appeal most to patients who want a tablet rather than an injectable biologic, who have had an inadequate response to apremilast, or who want to avoid the broader side-effect profile associated with older JAK1/2/3 inhibitors while still getting meaningfully better results than those drugs typically offer. As with other systemic immune-modulating therapies, candidates are screened for active infections, including tuberculosis, before starting.

Side Effects and Safety Considerations

The most commonly reported side effects in deucravacitinib’s trials were upper respiratory infections and nasopharyngitis, along with cold sores, canker sores, folliculitis, and acne, most of which were mild. Because it affects the immune system, deucravacitinib carries a general caution around infection risk, including reactivation of tuberculosis, and prescribing information notes that cases of certain cancers, including lymphoma, have been reported in people taking it, which is why ongoing monitoring matters even when a patient feels well. Routine blood work can also show modest increases in triglycerides, liver enzymes, or creatine phosphokinase (CPK), which your doctor will track over time. One point worth understanding clearly: because deucravacitinib’s allosteric mechanism selectively targets TYK2 rather than JAK1, JAK2, or JAK3, it has not been assigned the same FDA class-wide boxed warning — covering major cardiovascular events, blood clots, cancer, and mortality in at-risk patients — that applies to conventional JAK inhibitors like tofacitinib. That does not mean deucravacitinib is risk-free, but it is a genuine and clinically meaningful distinction worth raising directly with your prescribing doctor if this history is a concern for you.

Is Deucravacitinib Available in India? Cost Considerations

Deucravacitinib received its first approval from the US FDA in September 2022, followed by the European Medicines Agency in 2023. As of this writing, it has not been formally launched or commercially marketed by a local distributor in India the way some other psoriasis drugs have been, and it currently sits in an import-category for Indian patients. Several India-based specialty and trade-supply listings do advertise deucravacitinib tablets through import or named-patient channels, with quoted prices varying widely between listings and batch sizes — these online trade prices should be treated as rough, unverified reference points only, never as a quote. For how an oral systemic drug like this fits into the wider financial picture of psoriasis treatment in India, see our full psoriasis treatment cost guide, and always get a written, itemized estimate from your treating hospital or specialty pharmacy before committing.

Deucravacitinib vs Other Psoriasis Treatments: How Does It Compare?

Against apremilast, the other widely used oral systemic option, deucravacitinib’s head-to-head trial data shows a clear efficacy advantage, which is part of why it has been positioned as a step up for patients who want to stay on a pill. Against injectable biologics such as bimekizumab or risankizumab, deucravacitinib’s PASI 90 and PASI 100 rates generally sit lower, so patients chasing the deepest possible skin clearance may still do better with a biologic — the trade-off is convenience and route of administration rather than a simple “better or worse” comparison. Against older oral JAK inhibitors like tofacitinib, deucravacitinib’s selective, allosteric mechanism gives it a cleaner safety profile without the same boxed warning, at a cost that is likely to be substantially higher given its import-only status in India today. The right choice ultimately depends on disease severity, how quickly relief is needed, tolerance for injections, infection and cardiovascular history, and what is realistically accessible and affordable — a conversation best had directly with your treating dermatologist.

How This Fits Into Ayurvedic and Integrative Psoriasis Care

An oral immune-modulating drug like deucravacitinib and an Ayurvedic protocol approach psoriasis from very different directions — one directly interrupts a specific inflammatory signaling pathway, while Ayurveda works more gradually to address the broader constitutional imbalance it associates with chronic skin disease, including digestion, diet, and lifestyle factors. At our Ayurvedic psoriasis clinic in Bangalore, we regularly see patients who are either not yet candidates for a systemic drug, are weighing the cost and import logistics of a newer oral therapy, or want an integrative approach that supports skin health, gut health, and stress management alongside any conventional treatment they ultimately choose. Neither approach is universally superior; the right path depends on disease severity, cost tolerance, and personal preference. We have laid out a detailed, even-handed comparison in our Ayurveda vs biologics guide if you are weighing this kind of decision, and we are happy to discuss where integrative care might fit alongside a drug like deucravacitinib during an in-person consultation.

This article is for general education and does not replace a consultation with a qualified dermatologist. Dosing, candidacy, and monitoring decisions should always be made with your treating doctor.

---

Frequently Asked Questions

Sources

1. Deucravacitinib: Uses, Dosage, Side Effects & Warnings. Drugs.com.
2. Deucravacitinib Shown More Effective Than Apremilast in Phase 3 Trials. Pharmacy Times.
3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: POETYK PSO-2. Journal of the American Academy of Dermatology.
4. Deucravacitinib: Approval History and Mechanism. Wikipedia.
5. New Four-Year Sotyktu Data Demonstrate Durable Response Rates and Consistent Safety. Bristol Myers Squibb.
6. US FDA Approves First and Only TYK2 Inhibitor for the Treatment of Psoriatic Arthritis. Patient Care Online.